tbuckley/cabot-search huggingface dataset:
Heterochronic parabiosis reprograms the mouse brain transcriptome by shifting aging signatures in multiple cell types
Authors: Methodios Ximerakis, Kristina M. Holton, Richard M. Giadone, Ceren Ozek, Monika Saxena, Samara Santiago, Xian Adiconis, Danielle Dionne, Lan Nguyen, Kavya M. Shah, Jill M. Goldstein, Caterina Gasperini, Ioannis A. Gampierakis, Scott L. Lipnick, Sean K. Simmons, Sean M. Buchanan, Amy J. Wagers, Aviv Regev, Joshua Z. Levin, Lee L. Rubin
Journal: Nature Aging (2023)

Abstract Aging is a complex process involving transcriptomic changes associated with deterioration across multiple tissues and organs, including the brain. Recent studies using heterochronic parabiosis have shown that various aspects of aging-associated decline are modifiable or even reversible. To better understand how this occurs, we performed single-cell transcriptomic profiling of young and old mouse brains after parabiosis. For each cell type, we cataloged alterations in gene expression, molecular pathways, transcriptional networks, ligand–receptor interactions and senescence status. Our analyses identified gene signatures, demonstrating that heterochronic parabiosis regulates several hallmarks of aging in a cell-type-specific manner. Brain endothelial cells were found to be especially malleable to this intervention, exhibiting dynamic transcriptional changes that affect vascular structure and function. These findings suggest new strategies for slowing deterioration and driving regeneration in the aging brain through approaches that do not rely on disease-specific mechanisms or actions of individual circulating factors.
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
Authors: Elisabetta Sauta, Marie Robin, Matteo Bersanelli, Erica Travaglino, Manja Meggendorfer, Lin-Pierre Zhao, Juan Carlos Caballero Berrocal, Claudia Sala, Giulia Maggioni, Massimo Bernardi, Carmen Di Grazia, Luca Vago, Giulia Rivoli, Lorenza Borin, Saverio D'Amico, Cristina Astrid Tentori, Marta Ubezio, Alessia Campagna, Antonio Russo, Daniele Mannina, Luca Lanino, Patrizia Chiusolo, Luisa Giaccone, Maria Teresa Voso, Marta Riva, Esther Natalie Oliva, Matteo Zampini, Elena Riva, Olivier Nibourel, Marilena Bicchieri, Niccolo’ Bolli, Alessandro Rambaldi, Francesco Passamonti, Victor Savevski, Armando Santoro, Ulrich Germing, Shahram Kordasti, Valeria Santini, Maria Diez-Campelo, Guillermo Sanz, Francesc Sole, Wolfgang Kern, Uwe Platzbecker, Lionel Ades, Pierre Fenaux, Torsten Haferlach, Gastone Castellani, Matteo Giovanni Della Porta
Journal: Journal of Clinical Oncology (2023)

Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular prognostic model, the Molecular International Prognostic Scoring System (IPSS-M) was proposed to improve the prediction of clinical outcome of the currently available tool (Revised International Prognostic Scoring System [IPSS-R]). We aimed to provide an extensive validation of IPSS-M.
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance–Like Phenotype in Patients With Monoclonal Gammopathies
Authors: Leire Burgos, Luis-Esteban Tamariz-Amador, Noemi Puig, Maria-Teresa Cedena, Camila Guerrero, Tomas Jelínek, Sarah Johnson, Paolo Milani, Lourdes Cordon, Jose J. Perez, Marta Lasa, Rosalinda Termini, Albert Oriol, Miguel-Teodoro Hernandez, Luis Palomera, Rafael Martinez-Martinez, Javier de la Rubia, Felipe de Arriba, Rafael Rios, Maria-Esther Gonzalez, Mercedes Gironella, Valentin Cabañas, Maria Casanova, Isabel Krsnik, Albert Perez-Montaña, Verónica González-Calle, Paula Rodriguez-Otero, Vladimir Maisnar, Roman Hajek, Fritz Van Rhee, Victor Jimenez-Zepeda, Giovanni Palladini, Giampaolo Merlini, Alberto Orfao, Javier de la Cruz, Joaquin Martinez-Lopez, Juan-Jose Lahuerta, Laura Rosiñol, Joan Blade, Maria-Victoria Mateos, Jesus F. San-Miguel, Bruno Paiva
Journal: Journal of Clinical Oncology (2023)

The existence of patients with multiple myeloma (MM) and light-chain (AL) amyloidosis who present with a monoclonal gammopathy of undetermined significance (MGUS)-like phenotype has been hypothesized, but methods to identify this subgroup are not standardized and its clinical significance is not properly validated.An algorithm to identify patients having MGUS-like phenotype was developed on the basis of the percentages of total bone marrow (BM) plasma cells (PC) and of clonal PC within the BM PC compartment, determined at diagnosis using flow cytometry in 548 patients with MGUS and 2,011 patients with active MM. The clinical significance of the algorithm was tested and validated in 488 patients with smoldering MM, 3,870 patients with active MM and 211 patients with AL amyloidosis.Patients with smoldering MM with MGUS-like phenotype showed significantly lower rates of disease progression (4.5% and 0% at 2 years in two independent series). There were no statistically significant differences in time to progression between treatment versus observation in these patients. In active newly diagnosed MM, MGUS-like phenotype retained independent prognostic value in multivariate analyses of progression-free survival (PFS; hazard ratio [HR], 0.49; P = .001) and overall survival (OS; HR, 0.56; P = .039), together with International Staging System, lactate dehydrogenase, cytogenetic risk, transplant eligibility, and complete remission status. Transplant-eligible patients with active MM with MGUS-like phenotype showed PFS and OS rates at 5 years of 79% and 96%, respectively. In this subgroup, there were no differences in PFS and OS according to complete remission and measurable residual disease status. Application of the algorithm in two independent series of patients with AL predicted for different survival.We developed an open-access algorithm for the identification of MGUS-like patients with distinct clinical outcomes. This phenotypic classification could become part of the diagnostic workup of MM and AL amyloidosis.
Pediatric Ventilator Liberation Guideline: Should the T-Piece and Automatic Tube Compensation Be Ignored in the Spontaneous Breathing Trial?
Authors: Merve Havan, Hacer Uçmak, Tanıl Kendirli
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

"Pediatric Ventilator Liberation Guideline: Should the T-Piece and Automatic Tube Compensation Be Ignored in the Spontaneous Breathing Trial?." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp. –
Learning to lock down genetic diseases without throwing away the key
Authors: Phillip W.L. Tai, Jun Xie
Journal: Molecular Therapy (2023)

Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by progressive degeneration of α-motor neurons, resulting in muscle weakness and atrophy. 1 Crawford T.O. Pardo C.A. The neurobiology of childhood spinal muscular atrophy. Neurobiol. Dis. 1996; 3: 97-110 Crossref PubMed Scopus (420) Google Scholar The disease is caused by loss-of-function mutations in the survival motor neuron 1 gene (SMN1), affects approximately 1 in 11,000 newborns, and remains the leading genetic cause of infantile death. 1 Crawford T.O. Pardo C.A. The neurobiology of childhood spinal muscular atrophy. Neurobiol. Dis. 1996; 3: 97-110 Crossref PubMed Scopus (420) Google Scholar ,2 Lefebvre S. Bürglen L. Reboullet S. Clermont O. Burlet P. Viollet L. Benichou B. Cruaud C. Millasseau P. Zeviani M. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995; 80: 155-165 Abstract Full Text PDF PubMed Scopus (3177) Google Scholar ,3 Lunn M.R. Wang C.H. Spinal muscular atrophy. Lancet. 2008; 371: 2120-2133 Abstract Full Text Full Text PDF PubMed Scopus (641) Google Scholar ,4 Lorson C.L. Hahnen E. Androphy E.J. Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl. Acad. Sci. USA. 1999; 96: 6307-6311 Crossref PubMed Scopus (1227) Google Scholar Patients with SMA who enrolled into clinical trials for onasemnogene abeparvovec (brand name: Zolgensma), a systemically administered adeno-associated virus (AAV) vector that uses the AAV9 capsid to deliver SMN1 under the control of a strong and ubiquitously active promoter, 5 Mendell J.R. Al-Zaidy S. Shell R. Arnold W.D. Rodino-Klapac L.R. Prior T.W. Lowes L. Alfano L. Berry K. Church K. et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 2017; 377: 1713-1722 Crossref PubMed Scopus (1451) Google Scholar will soon enter their 10th year post-treatment. These patients and those who were among the first to receive the commercially approved gene therapy have permitted the evaluation of long-term outcomes in humans.
18-fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with non-tuberculous mycobacterial infections
Authors: Giacomo Stroffolini, Alberto Gaviraghi, Daniele Penna, Pavilio Piccioni, Francesco Venuti, Carlotta Botto, Michele Trezzi, Margherita Betti, Stelvio Sestini, Paola Anna Erba, Tommaso Lupia, Giovanni Di Perri, Stefano Aliberti, Andrea Calcagno
Journal: Journal of Infection (2023)
JACC Journals’ Pathway Forward With AI Tools
Authors: Valentin Fuster, Biykem Bozkurt, Y. Chandrashekhar, Julia Grapsa, Bonnie Ky, Douglas L. Mann, David J. Moliterno, Kalyanam Shivkumar, Candice K. Silversides, Justine Varieur Turco, Jian’an Wang
Journal: Journal of the American College of Cardiology (2023)
JACC Journals’ Pathway Forward With AI Tools
Authors: Valentin Fuster, Biykem Bozkurt, Y. Chandrashekhar, Julia Grapsa, Bonnie Ky, Douglas L. Mann, David J. Moliterno, Kalyanam Shivkumar, Candice K. Silversides, Justine Varieur Turco, Jian’an Wang
Journal: JACC. Cardiovascular imaging (2023)
JACC Journals’ Pathway Forward With AI Tools
Authors: Valentin Fuster, Biykem Bozkurt, Y. Chandrashekhar, Julia Grapsa, Bonnie Ky, Douglas L. Mann, David J. Moliterno, Kalyanam Shivkumar, Candice K. Silversides, Justine Varieur Turco, Jian’an Wang
Journal: JACC CardioOncology (2023)
Precise excision of HTLV-1 provirus with a designer-recombinase
Authors: Teresa Rojo-Romanos, Janet Karpinski, Sebastian Millen, Niklas Beschorner, Florian Simon, Maciej Paszkowski-Rogacz, Felix Lansing, Paul Martin Schneider, Jan Sonntag, Joachim Hauber, Andrea K. Thoma-Kress, Frank Buchholz
Journal: Molecular Therapy (2023)

The human T cell leukemia virus type 1 (HTLV-1) is a pathogenic retrovirus that persists as a provirus in the genome of infected cells and can lead to adult T cell leukemia (ATL). Worldwide, more than 10 million people are infected and approximately 5% of these individuals will develop ATL, a highly aggressive cancer that is currently incurable. In the last years, genome editing tools have emerged as promising antiviral agents. In this proof-of-concept study, we use substrate-linked directed evolution (SLiDE) to engineer Cre-derived site-specific recombinases to excise the HTLV-1 proviral genome from infected cells. We identified a conserved loxP-like sequence (loxHTLV) present in the long terminal repeats of the majority of virus isolates. After 181 cycles of SLiDE, we isolated a designer-recombinase (designated RecHTLV), which efficiently recombines the loxHTLV sequence in bacteria and human cells with high specificity. Expression of RecHTLV in human Jurkat T cells resulted in antiviral activity when challenged with an HTLV-1 infection. Moreover, expression of RecHTLV in chronically infected SP cells led to the excision of HTLV-1 proviral DNA. Our data suggest that recombinase-mediated excision of the HTLV-1 provirus represents a promising approach to reduce proviral load in HTLV-1-infected individuals, potentially preventing the development of HTLV-1-associated diseases. The human T cell leukemia virus type 1 (HTLV-1) is a pathogenic retrovirus that persists as a provirus in the genome of infected cells and can lead to adult T cell leukemia (ATL). Worldwide, more than 10 million people are infected and approximately 5% of these individuals will develop ATL, a highly aggressive cancer that is currently incurable. In the last years, genome editing tools have emerged as promising antiviral agents. In this proof-of-concept study, we use substrate-linked directed evolution (SLiDE) to engineer Cre-derived site-specific recombinases to excise the HTLV-1 proviral genome from infected cells. We identified a conserved loxP-like sequence (loxHTLV) present in the long terminal repeats of the majority of virus isolates. After 181 cycles of SLiDE, we isolated a designer-recombinase (designated RecHTLV), which efficiently recombines the loxHTLV sequence in bacteria and human cells with high specificity. Expression of RecHTLV in human Jurkat T cells resulted in antiviral activity when challenged with an HTLV-1 infection. Moreover, expression of RecHTLV in chronically infected SP cells led to the excision of HTLV-1 proviral DNA. Our data suggest that recombinase-mediated excision of the HTLV-1 provirus represents a promising approach to reduce proviral load in HTLV-1-infected individuals, potentially preventing the development of HTLV-1-associated diseases.
JACC Journals’ Pathway Forward With AI Tools
Authors: Valentin Fuster, Biykem Bozkurt, Y. Chandrashekhar, Julia Grapsa, Bonnie Ky, Douglas L. Mann, David J. Moliterno, Kalyanam Shivkumar, Candice K. Silversides, Justine Varieur Turco, Jian’an Wang
Journal: JACC Heart Failure (2023)
Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data
Authors: Deidre Wilkins, Annefleur C Langedijk, Robert Jan Lebbink, Christopher Morehouse, Michael E Abram, Bahar Ahani, Anastasia A Aksyuk, Eugenio Baraldi, Tyler Brady, Albert Tian Chen, Hsin Chi, Eun Hwa Choi, Robert Cohen, Daria M Danilenko, Vancheswaran Gopalakrishnan, Anne Greenough, Terho Heikkinen, Mitsuaki Hosoya, Christian Keller, Elizabeth J Kelly, Leyla Kragten-Tabatabaie, Federico Martinón-Torres, Abiel Homero Mascareñas de Los Santos, Marta C Nunes, María Angélica Palomino, Jesse Papenburg, Jeffrey M Pernica, Peter Richmond, Renato T Stein, Kevin M Tuffy, Charl Verwey, Mark T Esser, David E Tabor, Louis J Bont, Pascale Clement, Atul Gupta, Koichi Hashimoto, Kseniya Komissarova, Matt Laubscher, Magali Lumertz, Elena Priante, Irene Rivero-Calle, Ushma Wadia, Ki Wook Yun
Journal: The Lancet Infectious Diseases (2023)
A ciprofloxacin derivative with four mechanisms of action overcomes paclitaxel resistance in p53-mutant and MDR1 gene-expressing type II human endometrial cancer
Authors: Suhaila O. Alhaj-Suliman, Youssef W. Naguib, Emad I. Wafa, Sanjib Saha, Kareem Ebeid, Xiangbing Meng, Hamada H. Mohammed, Gamal El-Din A. Abuo-Rahma, Shujie Yang, Aliasger K. Salem
Journal: Biomaterials (2023)
Association of confluent and reticulated papillomatosis with obesity and resolution after treatment with doxycycline: A retrospective cohort study
Authors: Alyce M. Kuo, Samir Kamat, Tyler J. D’Ovidio, Rebecca Z. Zhou, Nicole Zatorski, Nanette B. Silverberg, Justine Fenner
Journal: Journal of the American Academy of Dermatology (2023)
Climate change, animals, and Candida auris: insights into the ecological niche of a new species from a One Health approach
Authors: Victor Garcia-Bustos, Marta Dafne Cabañero-Navalon, Alba Ruiz-Gaitán, Miguel Salavert, María Ángeles Tormo-Mas, Javier Pemán
Journal: Clinical Microbiology and Infection (2023)
Mesenchymal Stem Cell Culture within Perfusion Bioreactors Incorporating 3D‐Printed Scaffolds Enables Improved Extracellular Vesicle Yield with Preserved Bioactivity
Authors: Stephanie M. Kronstadt, Divya B. Patel, Louis J. Born, Daniel Levy, Max J. Lerman, Bhushan Mahadik, Shannon T. McLoughlin, Arafat Fasuyi, Lauren Fowlkes, Lauren Hoorens Van Heyningen, Amaya Aranda, Sanaz Nourmohammadi Abadchi, Kai‐Hua Chang, Angela Ting Wei Hsu, Sameer Bengali, John W. Harmon, John P. Fisher, Steven M. Jay
Journal: Advanced Healthcare Materials (2023)

Abstract Extracellular vesicles (EVs) are implicated as promising therapeutics and drug delivery vehicles in various diseases. However, successful clinical translation will depend on the development of scalable biomanufacturing approaches, especially due to the documented low levels of intrinsic EV‐associated cargo that may necessitate repeated doses to achieve clinical benefit in certain applications. Thus, here the effects of a 3D‐printed scaffold‐perfusion bioreactor system are assessed on the production and bioactivity of EVs secreted from bone marrow‐derived mesenchymal stem cells (MSCs), a cell type widely implicated in generating EVs with therapeutic potential. The results indicate that perfusion bioreactor culture induces an ≈40‐80‐fold increase (depending on measurement method) in MSC EV production compared to conventional cell culture. Additionally, MSC EVs generated using the perfusion bioreactor system significantly improve wound healing in a diabetic mouse model, with increased CD31 + staining in wound bed tissue compared to animals treated with flask cell culture‐generated MSC EVs. Overall, this study establishes a promising solution to a major EV translational bottleneck, with the capacity for tunability for specific applications and general improvement alongside advancements in 3D‐printing technologies.
Removal of an impacted migrated biliary stent with cholangioscopy: lights, camera, action
Authors: Radhika Chavan, Chaiti Gandhi, Vatsal Bachkaniwala, Milan Jolapara, Sanjay Rajput
Journal: Endoscopy (2023)

A 50-year-old woman was referred for removal of an internally migrated biliary stent. Fluoroscopy showed the migrated biliary stent and cholecystectomy clips ([Fig. 1]). She underwent endoscopic retrograde cholangiopancreatography (ERCP) and a biliary balloon was passed over the guidewire. Balloon sweeping was done; however, on sweeping, fresh blood was noticed emerging through the papilla. The procedure was therefore abandoned and a 7-Fr, 10-cm double-pigtail plastic stent (DPPS) was placed alongside the migrated stent. On day 3, the patient presented with severe anemia and hypotension. Contrast-enhanced computed tomography angiography (CTA) showed a right hepatic artery pseudoaneurysm, with an adjacent hematoma. She underwent conventional angiography and angioembolization with cyanoacrylate ([Fig. 2]).
Successful treatment using balloon-assisted enteroscopy for jejunal loop variceal bleeding after pancreaticoduodenectomy
Authors: Natsumi Maeda, Hirotsugu Maruyama, Akira Higashimori, Masaki Ominami, Shusei Fukunaga, Yasuaki Nagami, Yasuhiro Fujiwara
Journal: Endoscopy (2023)

Management of jejunal variceal bleeding after pancreaticoduodenectomy can be difficult. Previously, these cases were treated by portal vein stenting or shunt operations, resulting in a high likelihood of rebleeding. Endoscopic management could provide an alternative to invasive surgery; however, few reports have demonstrated endoscopic treatment [1] [2] [3] [4]. We report a successful case of balloon-assisted enteroscopy for jejunal loop variceal bleeding.
Endoscopic transgastric extraction of a prophylactic pancreatic single-pigtail plastic stent that had previously migrated into the caudal part of the Wirsung duct
Authors: Severine Ghuysen, Alexandru Lupu, Jérôme Rivory, Jean-Christophe Saurin, Florian Rostain, Thierry Ponchon, Mathieu Pioche
Journal: Endoscopy (2023)

We present the case of a 50-year-old patient who had undergone a previous endoscopic ampullectomy. A 5-Fr single-pigtail plastic stent was inserted into the Wirsung duct in order to prevent postresection acute pancreatitis [1]. Unfortunately, the stent immediately migrated distally into the pancreatic duct, was impossible to extract on endoscopy, and later lead to severe necrotizing pancreatitis of the body and tail of the pancreas. The patient remained septic and the perisplenic necrotic cavities were filled with collected necrotic material ([Fig. 1]), so we performed endoscopic ultrasound (EUS)-guided drainage using a fully covered lumen-apposing metal stent (LAMS; Axios; Boston Scientific, USA) ([Fig. 2] and [Fig. 3 a]) [2]. Despite this leading to a rapid amelioration of the necrotizing pancreatitis, there remained the problem of the migrated intrapancreatic stent.
Hemostasis using a large spherical electrode device for bleeding due to endoscopic sphincterotomy
Authors: Hiroki Kato, Makoto Kobayashi, Hideyuki Chiba, Motoyoshi Yano
Journal: Endoscopy (2023)

Endoscopic hemostasis is the first choice for bleeding due to endoscopic sphincterotomy (EST). Various methods are available, including local injection, clipping, balloon compression, and coagulation, each with its advantages and disadvantages [1]. Hemostatic forceps interfere with the forceps erecting mechanism, and there is currently no absolute device for coagulation hemostasis.
Off-label use of novel hemostatic gel to treat wound dehiscence after stapled hemorrhoidectomy
Authors: Claudio Zulli, Mario Gagliardi, Michele Fusco, Carmela Abbatiello, Mariano Sica, Attilio Maurano
Journal: Endoscopy (2023)

A 54-year-old man complaining of massive rectal bleeding and severe anemia was referred to our endoscopic center by the surgical unit. He had undergone stapled hemorrhoidectomy with Longo's technique 3 weeks before, and had received topical steroid and mesalamine therapy for 1 week without clinical improvement.
Use of a traction device facilitates opening of the pocket during the pocket-creation method of gastric endoscopic submucosal dissection
Authors: Masafumi Kitamura, Yoshimasa Miura, Hisashi Fukuda, Haruo Takahashi, Yuji Ino, Alan Kawarai Lefor, Hironori Yamamoto
Journal: Endoscopy (2023)

The pocket-creation method (PCM) is a strategy to achieve safe and high quality endoscopic submucosal dissection (ESD) throughout the alimentary tract [1] [2] [3] [4]. While the pocket is being created, the PCM enables endoscopists to effectively apply traction and countertraction using the tip of the hood alone. In this phase, the PCM can be considered a traction method; however, because stabilization of the endoscope tip and traction force gradually reduces while the pocket is being opened, it may become difficult and time-consuming. Particularly during gastric ESD, it is difficult to change the patient's position and, as a result, it may not be possible to use gravity effectively, depending on the location of the lesion. We devised a new strategy for the PCM using traction devices when opening the pocket during gastric ESD ([Fig. 1]), as we have reported in the past for colorectal ESD [5].
Endobiliary radiofrequency ablation of an intraductal vessel in a patient with surgically altered anatomy
Authors: Fred Karaisz, Anna C. Amaral, Waleed K. Hussain, Samuel Han
Journal: Endoscopy (2023)

A 49-year-old man with a history of chronic pancreatitis following Whipple procedure presented with hematemesis and hematochezia. Enteroscopy revealed blood throughout the afferent and efferent limbs, with a clot at the hepaticojejunostomy anastomosis ([Fig. 1]). Two subsequent endoscopic retrograde cholangiopancreatography (ERCP) procedures were performed to remove the blood clots ([Fig. 2]) and place biliary stents to manage the hemobilia. Owing to ongoing bleeding, the patient underwent empiric embolization of the left and right hepatic arteries. Despite these efforts, the patient's bleeding persisted, with associated hemodynamic instability. After a multidisciplinary discussion, the patient was offered salvage endobiliary radiofrequency ablation (RFA).
Successful hemostasis of multiple parapapillary diverticular hemorrhage by clip-with-rubber-band traction technique at the descending duodenum
Authors: Wulian Lin, Dazhou Li, Xiaojian He, Haitao Li, Wen Wang
Journal: Endoscopy (2023)

Various traction devices and techniques have been used to facilitate endoscopic submucosal dissection by creating a clear field of vision and allowing dissections to be performed more quickly and safely [1]. Here, we report successful endoscopic hemostasis of parapapillary diverticular hemorrhage by the clip-with-rubber-band traction technique at the descending duodenum.